(Q44391942)

2 December 2017

Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy (English)

1 reference

2 December 2017

1 reference

Demetrio Tallarico

1

1 reference

2 December 2017

Vito Rizzo

2

1 reference

2 December 2017

Fernando Di Maio

3

1 reference

2 December 2017

Federica Petretto

4

1 reference

2 December 2017

Gianluca Bianco

5

1 reference

2 December 2017

Giuseppe Placanica

6

1 reference

2 December 2017

Marta Marziali

7

1 reference

2 December 2017

Vincenzo Paravati

8

1 reference

2 December 2017

Nicolò Gueli

9

1 reference

2 December 2017

Fortunato Meloni

10

1 reference

2 December 2017

Stefano Villatico Campbell

11

1 reference

2 December 2017

1 March 2003

1 reference

2 December 2017

1 reference

2 December 2017

54

1 reference

2 December 2017

2

1 reference

2 December 2017

219-227

1 reference

Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells

2 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Quantitative hemodynamics by Doppler echocardiography: a noninvasive alternative to cardiac catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Alterations in left ventricular diastolic function with doxorubicin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

[(3)H]-trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Cardiac dysfunction late after cardiotoxic therapy for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400212

10.1177/000331970305400212

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference